格隆汇4月30日丨山水水泥(00691.HK)发布截至2026年3月31日止三个月第一季度报告。经营收入11.76 亿元，公司股东应占亏损7.16亿元，同比扩大约19.3%。 ...

To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

公司业绩与战略调整 - 国际纸业在2024年第一季度扭亏为盈，实现盈利 [1] - 公司正在为将其北美业务与海外业务进行拆分做准备 [1]

公司财务表现 - 截至2026年3月31日止三个月，公司取得经营收入11.76亿元人民币，同比减少27.47% [1] - 同期，公司股东应占亏损为7.16亿元人民币，同比扩大19.31% [1]

核心经济数据 - 2026年3月核心个人消费支出价格指数（剔除食品和能源）环比增长0.3%，推动12个月通胀率升至3.2%，与市场预期一致 [1] - 包含波动较大的汽油和食品杂货的总体PCE指数环比增长0.7%，年率升至3.5%，同样符合预期 [2] - 2026年第一季度实际国内生产总值按季节调整的年率增长2.0%，高于2025年第四季度的0.5%，但低于市场预期的2.2% [2] 关键影响因素 - 伊朗战争导致油价飙升，是推动消费者面临物价上涨的关键因素 [1] - 油价上涨为美联储的货币政策带来了新的挑战 [1]

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. ...

Chipotle Mexican Grill reported first-quarter comparable restaurant sales growth of 0.5%, reversing a string of recent declines, as customer traffic returned to its restaurants. Analysts had penciled in a 0.7% decline, per CNBC. Chipotle also repurchased $700.8 million of its own stock during the quarter at an average price of $36.14 per share. As of March 31, 2026, $1.0 billion remained available under its board-authorized repurchase program. Chipotle stock rose about 3% in after-hours trading following th ...

服务介绍 - 亚洲价值与护城河股票研究服务专注于为价值投资者寻找亚洲上市股票 其核心理念是利用价格与内在价值之间的巨大差距进行投资[1] - 该服务主要关注两类投资机会：深度价值资产负债表廉价股和宽护城河股票[1] - 深度价值资产负债表廉价股策略侧重于以折价购买资产 例如净现金股票 净流动资产价值股 低市净率股票和分拆价值折扣股[1] - 宽护城河股票策略侧重于以折价购买优秀公司的盈利潜力 例如“神奇公式”股票 高质量企业 隐形冠军和具有宽护城河的复利型企业[1] 分析师背景 - 分析师“价值钟摆”是亚洲股票市场专家 在买方和卖方均有超过十年的从业经验[1] - 该分析师是亚洲价值与护城河股票投资研究小组的作者 为寻求亚洲投资机会的价值投资者提供投资思路[1] - 该分析师尤其专注于香港市场 致力于寻找深度价值资产负债表廉价股和宽护城河股票[1] - 在其投资研究小组内 该分析师提供一系列观察名单并每月进行更新[1]

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. ...

AstraZeneca set its $80 billion revenue target for 2030 at an investor event in May 2024, when the consensus analyst estimate for that year sat around $67 billion. Few believed it, Sarin said, describing it as "a very stretch goal at the time." But leadership could see enough pipeline assets to justify the ambition if those bets paid off. She frames progress toward that goal around three building blocks. The first is existing products in approved indications, grown across the company's presence in more than ...